Filana Therapeutics (FLNA) vs NanoViricides (NNVC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NanoViricides (NNVC) has outperformed Filana Therapeutics (FLNA) over the past year, losing 10.2% versus a loss of 77.7%. Over five years, NNVC leads with a -76.5% price change compared with -98.9% for FLNA. Filana Therapeutics is the larger company by market cap ($32.3 million vs $29.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLNA | NNVC |
|---|---|---|
| Share price | $0.6413 | $1.14 |
| Market cap | $32.26M | $29.13M |
| 1-day change | +14.52% | -2.56% |
| YTD return | -67.61% | +0.88% |
| 1-year return | -77.66% | -10.24% |
| 5-year return | -98.85% | -76.54% |
| EPS (TTM) | $-0.87 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-90.97M | $-8.22M |
| 52-week high | $3.45 | $1.93 |
| 52-week low | $0.39 | $0.85 |
| Distance from 52-week high | -81.41% | -40.93% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +913.57% | +426.32% |
| Average volume | 2.09M | 356.86K |
| Shares outstanding | 50.30M | 25.55M |
| Employees | 17 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed FLNA by 67.4 percentage points over the past year.
About Filana Therapeutics
FLNA stock →Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
FLNA vs NNVC FAQ
Which is bigger, Filana Therapeutics or NanoViricides?
Filana Therapeutics (FLNA) is larger, with a market capitalization of $32.26M compared with $29.13M for NanoViricides (NNVC).
Which stock has performed better over the past year, FLNA or NNVC?
NNVC returned -10.24% over the past 12 months, compared with -77.66% for FLNA (price return, excluding dividends). Past performance does not predict future results.
Are Filana Therapeutics and NanoViricides in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.